Three-drug combo for advanced soft tissue sarcoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a new combination of three drugs (zanzalintinib, ipilimumab, and nivolumab) for people with soft tissue sarcoma that has spread. The goal is to see if this combination can shrink or slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have soft tissue sarcoma that has spread to other parts of the body or cannot be removed with surgery.
- You have had at least 1 but no more than 3 previous treatments for your cancer, and it has gotten worse on your last treatment.
- You have not had prior treatment with a drug like zanzalintinib, cabozantinib, or certain immunotherapies (nivolumab, ipilimumab, pembrolizumab, atezolizumab, etc.).
- You are 18 years or older and in relatively good health (able to do daily activities without major help).
- Your blood counts and organ function (kidney, liver, heart) are within a certain range, and you're not pregnant/breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests trabectedin plus ipilimumab and nivolumab in people with advanced soft-tissue sarcoma that has already been treated. It aims to see how well this combination works and how safely it can be given.
This trial is looking at whether a new combination of two drugs, zanzalintinib and pembrolizumab, can help people with certain types of advanced soft-tissue sarcoma that have not responded to other treatments. It aims to find out if the combination is safe and effective.
This trial tests a combination of three drugs (liposomal irinotecan, temozolomide, and bevacizumab) for people with advanced soft tissue sarcoma that has spread or cannot be removed by surgery. The goal is to see if this combination can help when other treatments have stopped working.
This trial tests a combination of chemotherapy, radiation, and two newer drugs (anlotinib and bempegaldesleukin) for people with advanced soft tissue sarcoma that cannot be removed by surgery. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests a combination of a PARP inhibitor drug, targeted radiation (SBRT), and immunotherapy for people with advanced sarcoma that has spread. It aims to see if this triple therapy can shrink tumors or slow the disease.
This trial tests a new immunotherapy drug (envafolimab) combined with two chemotherapy drugs (doxorubicin and ifosfamide) for people with advanced soft tissue sarcoma who have not had prior treatment. The goal is to see if this combination is safe and effective.
Hear when a new Metastatic Soft Tissue Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.